Spurned by FDA on an­oth­er im­munother­a­py, Agenus holds up ear­ly da­ta for CT­LA-4 drug across tu­mor types

In a Phase I study across nine tu­mor types, Agenus’ CT­LA-4 drug AGN1181 post­ed one com­plete re­sponse and three par­tial re­spons­es as a monother­a­py, of­fer­ing a key ef­fi­ca­cy base­line as the biotech pur­sues a com­bi­na­tion strat­e­gy with in-house PD-(L)1 drug bal­stil­imab, ac­cord­ing to da­ta pre­sent­ed Fri­day at SITC.

Three of those re­spon­ders ex­pressed the low affin­i­ty FcγRI­I­IA re­cep­tor, Agenus said, which is as­so­ci­at­ed with a lack of re­sponse to first-gen­er­a­tion CT­LA-4 in­hibitors. This Phase I study most­ly en­rolled heav­i­ly pre­treat­ed pa­tients with more than half hav­ing un­der­gone three or more pri­or lines of ther­a­py and one-third hav­ing re­ceived a pri­or PD-(L)1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER